ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the USA (Podcast Pearls)

PDF
Experts from the USA provide their thoughts on recent advances with immune checkpoint therapy for advanced urothelial carcinoma.

Released: March 19, 2021

Expiration: March 18, 2022

No longer available for credit.

Share

Faculty

Petros Grivas

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Jonathan Rosenberg

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York